The global clot busting drugs market is estimated to reach a market value of around USD 28.8 Billion in 2022, with the global market estimated to surge ahead at a CAGR value of 7.3% to reach a valuation of USD 58.4 Billion by the end of 2032. The injectable route of administration is driving the global clot busting drugs market as of 2021.
Market Outlook:
|
Data |
Market Insight |
|---|---|
|
Estimated market Value 2022 |
USD 28.8 Billion |
|
Estimated market Value 2032 |
USD 58.4 Billion |
|
CAGR of 2022 to 2032 |
7.3 % |
|
Market share of Top 5 countries |
57.4 % |
|
Key Market players |
Sanofi, Dr. Reddy’s Laboratories, Bayer AG, Boehringer Ingelheim Gmbh., Genentech Inc., Eli Lilly and Company, Johnson & Johnson Services Inc., The Medicines Company, Pfizer Inc. |
Abnormal blood clots are broken by clot-busting drugs. In the human body, a blood clot is a highly common and dangerous problem. A blood clot can obstruct veins and arteries, which can result in a hemorrhage, a stroke, or a heart attack. Clot-busting drugs work by breaking up aberrant blood clots and preserving regular blood flow.
Drugs that dissolve blood clots quickly help prevent many strokes. Clot-busting drugs can lessen the amount of brain damage that can result from a stroke by unblocking a clogged blood artery and restoring blood flow. Clot-busting medications must be administered within a few hours of the onset of stroke symptoms in order to be helpful.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The overall, clot busting drugs market sales account for approximately 17.3% of revenue share in the global cardiovascular drugs market, which was valued at around USD 155.6 Billion in 2021.
The global market for clot busting drugs recorded a historic CAGR of 7.3% in the last five years from 2016 to 2021.
The global market for clot busting drugs will be supported globally over the forecast period by the growing need for pharmaceuticals to treat heart attacks and strokes promptly. The development of clot busting therapeutic options and improvements in the pharmaceutical sector will further boost the growth of the global market for clot busting drugs.
Furthermore, as cardiovascular disorders like heart attacks and strokes become more common, the demand for clot busting drugs is anticipated to rise. The fifth most common cause of death in the USA is a stroke. The rising frequency of strokes needs an immediate response, and clot buster drugs can assist by dissolving the blood clot accumulating in the veins, which reduces blood pressure.
Strokes are increasing the rate of death in the population, which is causing the market for clot busting drugs to expand globally. Additionally, during the course of the forecast period, the increased risk of ischemic stroke in the global population is anticipated to boost the global market for clot busting drugs.
Additionally, stroke is the second leading cause of mortality worldwide, accounting for an estimated 5.5 million fatalities annually. Along with the enormous morbidity caused by stroke, which results in up to 50% of survivors having a long-term disability, there is also a significant mortality rate. As a result, stroke is a condition that is very important to public health and has major economic and social repercussions.
The global health impact of a stroke is expected to rise in the next years, especially in developing countries, which will boost the need for clot-busting drugs.
The cost of clot busting drugs that have shown to be particularly effective in treating ischemic stroke patients has more than doubled, considerably outpacing any Medicare/Medicaid reimbursements to hospitals that employ the medication.
Over the previous ten years, the price of alteplase (a clot busting drug) has climbed by 111%. According to Cardiovascular Business, the drug is particularly helpful in treating patients' acute ischemic stroke symptoms. If taken during the first few hours of a stroke, the medicine can frequently completely reverse its effects.
The global clot busting drugs market is thus likely to show high growth over the coming years a CAGR value of 7.3% and reach a global market size of USD 58.4 Billion by 2032.
During the projected period, there will be an increase in demand for pharmaceuticals to quickly treat heart attacks and strokes, which will lead to growth in the global market for clot-busting drugs. Developments in the pharmaceutical sector and the creation of clot-busting therapy options both influence the market's potential future expansion.
Tenecteplase, a newer generation clot busting medicine, outperforms the standard treatment for ischemic strokes in a number of critical areas, including improved health outcomes and lower costs, according to research that was conducted by the American Stroke Association.
The market for clot busting drugs will experience growth globally during the forecast period due to the increasing need for pharmaceutical products to promptly treat heart attacks and strokes.
For instance, non-fibrin-specific medications include plasminogen activating complex, streptokinase, and urokinase. Blood coagulation in the lungs is treated with urokinase, a drug of the serine protease class. Myocardial infarction, pulmonary embolism, and arterial thromboembolism are all conditions that are treated using the thrombolytic drug streptokinase.
The introduction of these innovative and better alternatives is expected to create a lucrative market for drug manufacturers and increase the adoption rate of their products, which will drive the Clot Busting drugs market in the projected period.
Principal Consultant
Drugs that target fibrin are fibrinolysis-inducing substances with negligible lytic effects, yet in stroke situations, they function as blood thinners. Tissue plasminogen activator (tPA), one of these medications, initiates the blood clots' disintegration when a stroked state is present.
The medication is exceedingly risky and should only be used under medical supervision due to the potential side effects of brain damage, paralysis, or even impaired speech. The tPA raises the likelihood of bleeding, it may not be possible for patients with a history of bleeding problems, recent operations, unstable blood pressure, or a recent severe concussion to get it.
A safe dose of the drug, which is administered intravenously, frequently does not remain in the bloodstream long enough to dissolve the large clots, and increasing the dose increases the risk of bleeding even though it is effective against smaller clots in thinner capillaries.
Additional adverse effects of these clot busting medications include bleeding from wounds or the area where the drug was shot, an allergic response, fever, reduced blood pressure, and signs of bleeding from other parts of the body, such as nosebleeds, black tarry stools, blood in the urine, and gum bleeding.
The aforementioned factors can serve as potential barriers to the expansion of the clot busting drugs market in the future.
The USA has dominated the North American region by reaching a worth of USD 8.4 Billion while withholding the vast majority of the worldwide market share of roughly 31.1% in 2021.
Nearly 8 lac strokes occur each year in the USA blood clot that blocks a vein supplying blood to the brain causes more than 85% of these strokes to be ischemic. The USA is anticipated to grow during the projected period for the same reason.
As of 2021, Germany has led the European clot busting drugs market withholding about 7.6% of the global market share. In Germany, between 30 to 40% of adults have excessive blood pressure. With age, the percentage rises. Every second individual is impacted starting around age 60. It may result in deadly outcomes such as cardiac arrhythmias, renal failure, a stroke, or a heart attack.
With a growing number of drug manufacturers for the conditions like stroke and an increasing pipeline of clot busting drugs, Germany clot busting drugs market is expected to show substantial growth over the projected period.
China accounted for USD 1.6 Billion withholding the majority of the East Asian market share as of 2021. With an aging population, China has made significant progress in reforming its healthcare system. It currently offers a basic kind of universal health insurance and generously subsidizes an expanding list of essential medications.
In an effort to make medicines, including certain products from Pfizer, GlaxoSmithKline, and Novartis, more affordable, China is expected to reduce the prices of roughly 400 drugs for respiratory disorders, fever, cardiovascular diseases, and pain by up to 20%. This is expected to boost the market for clot busting drugs in the future too within this region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By product, anticoagulants have driven the global market by achieving a valuation of about USD 9.9 Billion in 2021 withholding the majority of the global market share of about 36.7%. Due to the rise in chronic diseases, the development of anticoagulant medicines has become more molecularly and biologically advanced. Emerging nations are increasingly using novel oral anticoagulants (NOACs) and over the forecast period, increasing product launches and approvals are anticipated to support market expansion.
For instance, Natco Pharma introduced a rivaroxaban molecule under the trade name RPIGAT in December 2020. This anticoagulant drug is used to treat and prevent blood clots.
By indication, pulmonary embolism has led the global market by achieving a valuation of USD 8.4 Billion by the end of 2021. The demand for clot busting drugs is expected to increase because those who are receiving chemotherapy or who have a family history of pulmonary embolism are most at risk. The market is expected to thrive as the number of cancer patients increases.
In 2020, cancer was responsible for around 10 million deaths, according to the World Health Organization. Additionally, it is projected that rising government investments to enhance public healthcare systems will accelerate market expansion.
The injectable dominated the market in terms of route of administration and is predicted to continue expanding, accounting for more than half of the global market. The primary factors driving the growth of this market are the increasing use of biological drugs, the number of chronic diseases, the surge in sharps injuries, and the benefits of injectables. These problems have raised the demand for devices like safety syringes, prefilled syringes, and auto-injectors.
By distribution channel, hospital pharmacies have led the global market by generating nearly one-third of the global revenue as of 2021. The growing incidence of chronic diseases, patient compliance, and the wide & easy availability of a variety of products within the hospital premises are all responsible for the high percentage of this segment.
Tissue plasminogen activator (tPA) and thrombolytic drugs have changed how heart attack patients are treated, and they have sparked competition among pharmaceutical companies.
In order to introduce new technologies and therapies, major companies in the global market for clot busting drugs are investing in research and development operations. To acquire a competitive edge, several of the other companies want to get product approvals for their new items. For example,
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2016 to 2021 |
| Market Analysis | USD Billion for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; and Middle East & Africa (MEA). |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Rest of Latin America, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, Rest of Europe, Japan, China, South Korea, India, Thailand, Indonesia, Malaysia, Vietnam, Philippines, Australia, New Zealand, Turkey, GCC, South Africa, Israel, North Africa and Rest of MEA. |
| Key Market Segments Covered | Product, Indication, Route of Administration Distribution Channel and Regions. |
| Key Companies Profiled | Sanofi; Dr. Reddy’s Laboratories; Bayer AG; Boehringer Ingelheim Gmbh.; Genentech Inc.; Eli Lilly and Company; Johnson & Johnson Services Inc.; The Medicines Company; Pfizer Inc. |
| Pricing | Available upon Request |
The global clot busting drugs market is estimated to be worth USD 26.9 Billion at end of 2021.
The clot busting drugs market is expected to reach USD 58.4 Billion by end of 2032 growing at a CAGR of 7.3%.
Molecular and biological developments in clot busting drugs, new product approvals and launches, and increasing sedentary lifestyles among people leading to an increase in the prevalence of cardiovascular diseases are some of the key factors that drive this market.
The North American region has the highest market share of about 32.4% by the end of 2021 in the global clot busting drugs market.
South Asia is estimated to grow with a CAGR rate of 6.0% in the forecast duration of the global clot busting drugs market.
The USA, China, Germany, Japan, and the United Kingdom are the top five countries, which are expected to drive demand in the clot busting drugs market.
Sanofi, Dr. Reddy’s Laboratories, Bayer AG, Boehringer Ingelheim Gmbh., Genentech Inc., Eli Lilly and Company, Johnson & Johnson Services Inc., The Medicines Company, Pfizer Inc. are some of the key players in the clot busting drug industry.
From 2016 to 2021, the market for clot busting drugs expanded at the rate of 7.3%.
China accounted for 6.1% of the market share at the end of 2021 in the global market.
The United Kingdom displayed a market share of around 7.6% in 2021 in the global clot busting drugs market
1. Executive Summary | Clot Busting Drugs Market 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. Global Demand (in Value or Distribution Channel in USD Billion) Analysis 2016 to 2021 and Forecast, 2022 to 2032 7. Global Analysis 2016 to 2021 and Forecast 2022 to 2032, By Product 8.1. Thrombolytic Drugs 8.2. Anti-Platelet Drugs 8.3. Anticoagulants 8.4. Others 8. Global Analysis 2016 to 2021 and Forecast 2022 to 2032, By Indication 9.1. Pulmonary Embolism 9.2. Deep Vein Thrombosis 9.3. Atrial Fibrillation 9.4. Others 9. Global Analysis 2016 to 2021 and Forecast 2022 to 2032, By Route of Administration 10.1. Oral 10.2. Injectable 10. Global Analysis 2016 to 2021 and Forecast 2022 to 2032, By Distribution Channel 11.1. Hospital Pharmacy 11.2. Drug Store 11.3. Online Pharmacy 11.4. Retail Pharmacies 11. Global Analysis 2016 to 2021 and Forecast 2022 to 2032, By Region 12.1. North America 12.2. Latin America 12.3. Europe 12.4. East Asia 12.5. South Asia 12.6. Oceania 12.7. Middle East and Africa (MEA) 12. North America Analysis 2016 to 2021 and Forecast 2022 to 2032 13. Latin America Analysis 2016 to 2021 and Forecast 2022 to 2032 14. Europe Analysis 2016 to 2021 and Forecast 2022 to 2032 15. East Asia Analysis 2016 to 2021 and Forecast 2022 to 2032 16. South Asia Analysis 2016 to 2021 and Forecast 2022 to 2032 17. Oceania Analysis 2016 to 2021 and Forecast 2022 to 2032 18. Middle East and Africa (MEA) Analysis 2016 to 2021 and Forecast 2022 to 2032 19. Market Structure Analysis 20. Competition Analysis 21.1. Johnson & Johnson Services Inc. 21.2. Sanofi 21.3. Dr. Reddy’s Laboratories 21.4. Bayer AG 21.5. Boehringer Ingelheim GmbH 21.6. Genentech Inc. 21.7. Eli Lilly and Company 21.8. The Medicines Company 21.9. Pfizer Inc. 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Clot Busting Drugs Market
